List of dual GIP/GLP-1 receptor agonists: Uses, common brands, and safety information

Key takeaways

• Dual GIP/GLP-1 receptor agonists, like tirzepatide, may help control blood sugar and reduce appetite more effectively than GLP-1 agonists.

• Tirzepatide, known by the brand names Mounjaro and Zepbound, is currently the only FDA-approved dual agonist, with more drugs in development.

• These medications treat Type 2 diabetes, obesity, and weight-related conditions, often leading to significant weight loss.

• Common side effects include nausea, vomiting, and digestive issues, while serious risks include pancreatitis and gallbladder disease.